Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.
Saved in:
| Title: | Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience. |
|---|---|
| Authors: | Fogel, Lindsay1 (AUTHOR), Roney, Patrick C.2,3 (AUTHOR), Ahn, Jaeil2,3 (AUTHOR), Aleman, Adolfo4 (AUTHOR), Perez-Manon, Fideliza4 (AUTHOR), Arias-Orozco, Natalie4 (AUTHOR), Monteleone, Gabriella4 (AUTHOR), Londono, Kiara4 (AUTHOR), Builes, Kathleen4 (AUTHOR), Anand, Palka4 (AUTHOR), Parmar, Harsh4 (AUTHOR), Phull, Pooja4 (AUTHOR), Vesole, David4 (AUTHOR), Siegel, David S.4 (AUTHOR), Ip, Andrew1,4 (AUTHOR), Biran, Noa1,4 (AUTHOR) Noa.biran@hmhn.org |
| Source: | Leukemia & Lymphoma. Jan2026, Vol. 67 Issue 2, p366-376. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
